US-based medical technology companies GE HealthCare and Masimo have teamed up to integrate Masimo’s Signal Extraction Technology (SET) pulse oximetry into GE HealthCare’s Portrait Mobile platform.

The partnership builds on a long-standing relationship between the two companies in providing joint solutions for customers across the care continuum.

The integration of Masimo SET pulse oximetry with GE HealthCare’s Portrait Mobile platform will enable real-time continuous monitoring with a personalised view of the patient’s vitals.

It also facilitates the monitoring while the patients are in movement during critical recovery periods, specifically after surgery or discharge from the intensive care unit (ICU).

GE HealthCare monitoring solutions general manager Neal Sandy said: “Portrait Mobile is built as an open platform, with the capability to be compatible with other technologies.

“The ability to integrate Masimo’s innovative SET pulse oximetry in a wearable sensor demonstrates the flexibility and scalability of our new platform while leveraging Masimo’s measurement expertise.

“Clinicians and patients will see the real benefit as Portrait Mobile enhances clinical decision-making for mobile patients and ultimately, supports earlier detection of deterioration.”

Portrait Mobile is a wireless and wearable continuous patient monitoring solution that leverages advanced cloud-native technology to provide a real-time personalised view of the patient.

GE HealthCare offers the platform as part of its FlexAcuity monitoring solution, which combines hardware and software that adapts to rapidly changing patient needs.

In August this year, the US Food and Drug Administration (FDA) granted 510(k) approval for the Portrait Mobile platform.

Masimo’s SET Measure-through Motion and Low Perfusion pulse oximetry outperformed other pulse oximetry technologies in more than 100 independent and objective studies.

When used in post-surgical wards, SET has been shown to help reduce deaths due to opioid-induced respiratory depression, rapid response team activations and transfers back to the ICU.

The pulse oximetry solution has also reduced severe retinopathy of prematurity (ROP) in the NICU and improved critical congenital heart disease (CCHD) screening in newborns.

Masimo chief operating officer Bilal Muhsin said: “We are excited to build on our collaboration with GE HealthCare by providing integrated solutions to help our customers and optimise patient care.

“Through our expansion into mobile, wireless technologies, we are proud to incorporate Masimo SET pulse oximetry into the Portrait Mobile monitoring solution.”